Hospital
Cooley Dickinson Hospital INC
Cooley Dickinson Hospital INC was paid $34.78M by Medicaid between Jan 2018 and Dec 2024, across 363 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoCOOLEY DICKINSON HOSPITAL INC
NORTHAMPTON, MA 01060
NORTHAMPTON, MA 01060
33aNPI1477596310assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$34.78M
24GClaims1,312,197
24DCodes billed363
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Massachusetts
Rank by total paid#31 of 66
Median peer was paid$29.11M
This provider vs. median1.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 173,464 | $5.28M | |
| 2019 | 182,935 | $4.48M | |
| 2020 | 163,424 | $4.12M | |
| 2021 | 219,496 | $5.95M | |
| 2022 | 222,755 | $6.47M | |
| 2023 | 201,180 | $4.06M | |
| 2024incomplete | 148,943 | $4.42M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 38,587 | 34,280 | $5.31M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.0% | 10,395 | 8,838 | $3.12M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.2% | 52,014 | 18,402 | $2.84M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.3% | 17,985 | 16,605 | $2.54M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 10,283 | 8,846 | $1.59M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.4% | 3,151 | 2,087 | $1.19M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 18,020 | 16,028 | $1.08M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.8% | 2,036 | 1,953 | $975K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 6,539 | 4,915 | $679K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.9% | 27,429 | 10,527 | $655K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 5,430 | 5,130 | $592K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 10,997 | 4,717 | $477K |
351 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.3% | 5,474 | $469K |
| S9485 | Crisis intervention mental health services, per diem | 1.3% | 766 | $466K |
| G0378 | Hospital observation service, per hour | 1.2% | 3,615 | $426K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 4,717 | $384K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 911 | $377K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.1% | 564 | $373K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,978 | $331K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 10,948 | $321K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,574 | $316K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 77,836 | $288K |
| 97161 | <1% | 4,395 | $285K | |
| 97035 | <1% | 5,088 | $251K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,846 | $246K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,752 | $244K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,503 | $239K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 8,939 | $237K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 13,265 | $229K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,996 | $223K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,919 | $222K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,835 | $220K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,750 | $216K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,524 | $195K |
| 92526 | <1% | 3,097 | $190K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,377 | $189K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,474 | $172K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 3,622 | $167K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,265 | $165K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 6,563 | $165K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 826 | $157K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,152 | $152K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,003 | $151K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 839 | $150K |
| 97162 | <1% | 2,752 | $140K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 651 | $121K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,409 | $116K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 7,427 | $115K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,229 | $113K |
| ATP15 | <1% | 13,981 | $109K | |
| J3490 | Unclassified drugs | <1% | 5,710 | $108K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 807 | $103K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 448 | $97K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 527 | $95K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 799 | $95K |
| ATP14 | <1% | 19,834 | $93K | |
| 88142 | <1% | 6,652 | $92K | |
| 85027 | <1% | 26,807 | $90K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 947 | $89K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 444 | $87K |
| 93971 | <1% | 682 | $86K | |
| 96415 | <1% | 438 | $86K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 53,831 | $81K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,509 | $81K |
| 94060 | <1% | 1,154 | $75K | |
| 84703 | <1% | 11,988 | $75K | |
| 84484 | <1% | 10,009 | $74K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 15,545 | $69K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 14,065 | $67K |
| 76642 | <1% | 771 | $67K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,925 | $66K |
| 80050 | General health panel | <1% | 4,352 | $64K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,578 | $62K |
| 86803 | <1% | 6,803 | $60K | |
| 82728 | <1% | 7,889 | $60K | |
| ATP08 | <1% | 13,682 | $60K | |
| 80053 | Comprehensive metabolic panel | <1% | 42,621 | $60K |
| 83690 | <1% | 14,342 | $57K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 6,459 | $56K |
| 76830 | Ultrasound, transvaginal | <1% | 774 | $56K |
| 83735 | <1% | 17,874 | $56K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,265 | $55K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 926 | $55K |
| 73564 | <1% | 2,315 | $54K | |
| 87088 | <1% | 11,451 | $54K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,441 | $53K |
| 86618 | <1% | 2,491 | $50K | |
| 97165 | <1% | 649 | $48K | |
| 83655 | <1% | 3,832 | $48K | |
| 86140 | <1% | 16,357 | $45K | |
| 80076 | <1% | 29,226 | $44K | |
| 73630 | <1% | 1,861 | $44K | |
| 82607 | <1% | 6,345 | $44K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 323 | $43K |
| 83880 | <1% | 2,972 | $43K | |
| 80061 | Lipid panel | <1% | 18,773 | $42K |
| 97166 | <1% | 699 | $42K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 211 | $42K |
| 96367 | <1% | 332 | $41K | |
| 84403 | <1% | 2,573 | $41K | |
| 87081 | <1% | 6,779 | $40K | |
| 87205 | <1% | 14,607 | $37K | |
| 74183 | <1% | 166 | $37K | |
| 73610 | <1% | 1,345 | $36K | |
| 82670 | <1% | 1,814 | $35K | |
| ATP17 | <1% | 7,357 | $33K | |
| 87536 | <1% | 1,060 | $32K | |
| 94729 | <1% | 1,193 | $31K | |
| 87070 | <1% | 5,354 | $31K | |
| 86703 | <1% | 2,768 | $29K | |
| 86850 | <1% | 4,231 | $29K | |
| 72110 | <1% | 665 | $28K | |
| 73130 | <1% | 985 | $25K | |
| 73030 | <1% | 1,283 | $24K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,893 | $24K |
| 85651 | <1% | 11,191 | $23K | |
| 87186 | <1% | 4,832 | $23K | |
| 85610 | <1% | 14,504 | $23K | |
| 82784 | <1% | 3,738 | $23K | |
| 87340 | <1% | 3,119 | $22K | |
| 84439 | <1% | 4,601 | $21K | |
| 84702 | <1% | 1,743 | $21K | |
| 87040 | <1% | 2,181 | $19K | |
| 83550 | <1% | 4,910 | $19K | |
| 94726 | <1% | 478 | $18K | |
| 81001 | <1% | 11,992 | $18K | |
| 83605 | <1% | 2,784 | $17K | |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | <1% | 24 | $17K |
| 76536 | <1% | 194 | $17K | |
| 87077 | <1% | 4,086 | $17K | |
| 83540 | <1% | 5,498 | $16K | |
| 84153 | <1% | 2,037 | $16K | |
| 77080 | <1% | 369 | $16K | |
| ATP03 | <1% | 3,946 | $16K | |
| 71250 | <1% | 524 | $16K | |
| 82746 | <1% | 2,419 | $15K | |
| 72141 | <1% | 137 | $15K | |
| 86762 | <1% | 1,355 | $15K | |
| 81003 | <1% | 11,944 | $14K | |
| 88342 | <1% | 1,277 | $14K | |
| 83970 | <1% | 929 | $14K | |
| 86038 | <1% | 1,883 | $13K | |
| 86787 | <1% | 1,322 | $13K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 14 | $12K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 523 | $12K |
| 83520 | <1% | 1,354 | $12K | |
| 73502 | <1% | 596 | $12K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 196 | $11K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 687 | $11K |
| 73110 | <1% | 459 | $11K | |
| 86360 | <1% | 722 | $10K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,470 | $10K |
| 88304 | <1% | 241 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 4,540 | $10K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 76 | $10K |
| 84146 | <1% | 858 | $10K | |
| 86706 | <1% | 1,444 | $9K | |
| 86592 | <1% | 3,186 | $9K | |
| 93017 | <1% | 107 | $9K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,037 | $9K |
| 80299 | <1% | 668 | $9K | |
| 86160 | <1% | 710 | $9K | |
| 82803 | <1% | 840 | $9K | |
| 86359 | <1% | 813 | $9K | |
| 80179 | <1% | 993 | $9K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 8,047 | $8K |
| 86900 | <1% | 4,183 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 63,173 | $8K |
| 85379 | <1% | 1,410 | $8K | |
| 59025 | Fetal non-stress test | <1% | 40 | $8K |
| 86901 | <1% | 4,183 | $7K | |
| 76775 | <1% | 78 | $7K | |
| 86480 | <1% | 189 | $7K | |
| 87522 | Neg quan hep c or qual rna | <1% | 298 | $7K |
| 76770 | <1% | 77 | $7K | |
| 83001 | <1% | 545 | $7K | |
| 86235 | <1% | 214 | $7K | |
| 97116 | <1% | 288 | $7K | |
| 87181 | <1% | 1,789 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,279 | $6K |
| 83516 | <1% | 657 | $6K | |
| 87209 | <1% | 543 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,299 | $6K |
| 82570 | <1% | 3,006 | $6K | |
| ATP07 | <1% | 1,262 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 9,597 | $6K |
| ATP16 | <1% | 912 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,780 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 205 | $6K |
| 97760 | <1% | 127 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,478 | $5K |
| 77065 | Tomosynthesis, mammo | <1% | 145 | $5K |
| ATP11 | <1% | 1,066 | $5K | |
| 36430 | <1% | 30 | $5K | |
| 90715 | <1% | 227 | $5K | |
| 82043 | <1% | 2,549 | $5K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 12 | $5K |
| 76604 | <1% | 57 | $4K | |
| 84402 | <1% | 308 | $4K | |
| 97167 | <1% | 57 | $4K | |
| 73221 | <1% | 27 | $4K | |
| 76882 | <1% | 72 | $4K | |
| 82105 | <1% | 386 | $4K | |
| 72050 | <1% | 92 | $4K | |
| 86612 | <1% | 368 | $4K | |
| ATP18 | <1% | 626 | $3K | |
| 80143 | <1% | 609 | $3K | |
| 82533 | <1% | 536 | $3K | |
| 86430 | <1% | 986 | $3K | |
| 84165 | <1% | 858 | $3K | |
| 80164 | <1% | 789 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,403 | $3K |
| 84100 | <1% | 4,147 | $3K | |
| 86364 | <1% | 1,319 | $3K | |
| 84460 | <1% | 1,388 | $3K | |
| 86225 | <1% | 392 | $3K | |
| 87177 | <1% | 523 | $3K | |
| 86481 | <1% | 65 | $3K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,219 | $3K |
| ATP10 | <1% | 737 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,152 | $3K |
| 86200 | <1% | 317 | $2K | |
| 71271 | <1% | 81 | $2K | |
| 82550 | <1% | 2,026 | $2K | |
| 72100 | <1% | 221 | $2K | |
| 12001 | <1% | 12 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 132 | $2K |
| 87046 | <1% | 375 | $2K | |
| 86039 | <1% | 298 | $2K | |
| 87045 | <1% | 361 | $2K | |
| 86769 | <1% | 93 | $2K | |
| 72072 | <1% | 39 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,854 | $2K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 24 | $2K |
| 86617 | <1% | 131 | $1K | |
| 87230 | <1% | 146 | $1K | |
| 85044 | <1% | 321 | $1K | |
| 94727 | <1% | 27 | $1K | |
| 70486 | <1% | 58 | $1K | |
| 0012A | <1% | 29 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 577 | $1K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 13 | $1K |
| 70491 | <1% | 14 | $1K | |
| 74018 | <1% | 89 | $1K | |
| 85007 | <1% | 798 | $1K | |
| 77061 | <1% | 37 | $1K | |
| 86334 | <1% | 134 | $1K | |
| 93308 | <1% | 14 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,524 | $1K |
| 82378 | <1% | 96 | $1K | |
| 83002 | <1% | 85 | $998.56 | |
| 83883 | <1% | 149 | $970.06 | |
| 82950 | <1% | 245 | $931.58 | |
| ATP02 | <1% | 297 | $930.05 | |
| 86376 | <1% | 95 | $928.90 | |
| 80178 | <1% | 360 | $914.40 | |
| 70496 | <1% | 14 | $903.27 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 38 | $839.48 |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 32 | $803.31 |
| 93976 | <1% | 13 | $799.78 | |
| 82530 | <1% | 101 | $790.13 | |
| 83615 | <1% | 1,215 | $776.73 | |
| 85730 | <1% | 104 | $772.35 | |
| 87634 | <1% | 12 | $768.36 | |
| 82150 | <1% | 168 | $720.35 | |
| 84550 | <1% | 1,361 | $687.21 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,654 | $679.20 |
| ATP09 | <1% | 118 | $623.96 | |
| 86308 | <1% | 146 | $593.12 | |
| 84450 | <1% | 766 | $590.76 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 93 | $579.72 |
| 84156 | <1% | 319 | $543.75 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 374 | $536.44 |
| 84481 | <1% | 53 | $532.30 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,134 | $532.10 |
| 86255 | <1% | 59 | $454.48 | |
| 73140 | <1% | 25 | $450.09 | |
| 87484 | <1% | 95 | $415.50 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,178 | $396.13 |
| 83993 | <1% | 29 | $389.04 | |
| 86765 | <1% | 50 | $383.30 | |
| 0011A | <1% | 18 | $372.68 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,758 | $367.85 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 376 | $366.14 |
| 86704 | <1% | 60 | $356.13 | |
| 87641 | <1% | 22 | $352.11 | |
| 86161 | <1% | 45 | $346.64 | |
| 83721 | <1% | 64 | $330.30 | |
| 87469 | <1% | 71 | $277.00 | |
| 86325 | <1% | 15 | $271.40 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,838 | $259.90 |
| 84155 | <1% | 602 | $250.42 | |
| 83921 | <1% | 30 | $217.72 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,225 | $208.39 |
| 82274 | <1% | 29 | $203.14 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 432 | $199.47 |
| 70498 | <1% | 12 | $192.61 | |
| 82785 | <1% | 13 | $188.76 | |
| 82565 | <1% | 553 | $184.79 | |
| 96376 | <1% | 1,346 | $173.40 | |
| 86708 | <1% | 24 | $166.54 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 603 | $149.97 |
| 82553 | <1% | 24 | $147.56 | |
| 86800 | <1% | 12 | $145.10 | |
| 82627 | <1% | 12 | $141.96 | |
| 86695 | <1% | 13 | $136.00 | |
| 82248 | <1% | 892 | $135.53 | |
| 81015 | <1% | 86 | $125.52 | |
| 85018 | <1% | 54 | $108.00 | |
| 82140 | <1% | 25 | $103.68 | |
| 84480 | <1% | 13 | $103.52 | |
| 87329 | <1% | 13 | $95.28 | |
| 82390 | <1% | 15 | $88.20 | |
| 80175 | <1% | 14 | $84.63 | |
| 73590 | <1% | 12 | $67.37 | |
| 82542 | <1% | 15 | $55.86 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 60 | $55.56 |
| 82272 | <1% | 24 | $52.38 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 236 | $47.34 |
| 87210 | <1% | 15 | $35.88 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 99 | $31.80 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 836 | $27.78 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 35 | $27.02 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 238 | $25.13 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,533 | $20.13 |
| 82247 | <1% | 13 | $13.71 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,574 | $11.39 |
| 82947 | <1% | 16 | $8.10 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 1,165 | $3.82 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 241 | $1.46 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 872 | $1.04 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 71 | $0.00 |
| 82962 | 0% | 2,248 | $0.00 | |
| 36591 | 0% | 42 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 655 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 112 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 62 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 27 | $0.00 |
| 94760 | 0% | 66 | $0.00 | |
| 87493 | 0% | 134 | $0.00 | |
| 80320 | 0% | 286 | $0.00 | |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 65 | $0.00 |
| 80069 | 0% | 143 | $0.00 | |
| 80329 | 0% | 193 | $0.00 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 56 | $0.00 |
| 83521 | 0% | 24 | $0.00 | |
| 99156 | 0% | 41 | $0.00 | |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | 0% | 47 | $0.00 |
| C1769 | Guide wire | 0% | 13 | $0.00 |
| 91301 | 0% | 13 | $0.00 | |
| 87625 | 0% | 12 | $0.00 | |
| 84520 | 0% | 94 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 342 | $0.00 |
| 96417 | 0% | 147 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 409 | $0.00 |
| 99152 | 0% | 103 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 87 | $0.00 |
| 84145 | 0% | 37 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 60 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 48 | $0.00 |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 56 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAMOUREUX, LAURIE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Vna & Hospice of Cooley Dickinson INC | Northampton, MA | $866K |
| Vna & Hospice of Cooley Dickinson INC | Northampton, MA | $583K |
| Cooley Dickinson Hospital INC | Southampton, MA | $203K |
| Cooley Dickinson Hospital INC | Northampton, MA | $14K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.